The aim of the clinical study is to determine the safety, reactogenicity and immunogenicity parameters of the EpiVacCorona vaccine in volunteers aged 18-60 years. The research tasks are to: - evaluate the safety of the EpiVacCorona vaccine when administered twice intramuscularly; - evaluate the reactogenicity of the EpiVacCorona vaccine when administered twice intramuscularly; - identify the development of adverse reactions to vaccine administration; - study the humoral and cellular immune responses following two doses of the EpiVacCorona vaccine.
The first phase of the clinical trial is an open trial. The study will enroll 14 men and
women aged 18 to 30 years, inclusive, who meet the inclusion criteria and have no exclusion
criteria, whose data will be used for subsequent analysis of safety and immunogenicity.
The second phase of the clinical trial is a simple, blind, placebo-controlled, randomized,
parallel-group study. The study will enroll 86 men and women aged 18 to 60 years, inclusive,
who meet the inclusion criteria and have no exclusion criteria whose, the data will be used
for subsequent analysis of safety and immunogenicity.
If volunteers drop out of the study, they will not be replaced.
Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.
Other: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)
The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)
1. Availability of a signed and dated informed consent of the volunteer to participate in
a clinical trial, prior to any of the study procedures.
2. Verified diagnosis is "healthy" according to the data of the standard clinical,
laboratory and instrumental examination methods.
3. Age from 18 to 60 years old inclusive.
4. Body mass index from 18.5 to 30 kg / m3.
5. Ability to attend all scheduled visits and all planned procedures and examinations.
6. Consent of volunteers to use effective contraceptive methods throughout the study,
including the observation period for possible post-vaccination reactions.
Exclusion Criteria:
1. Contacts with COVID-19 patients for 14 days prior to the start of the clinical trial.
2. Hypersensitivity to any component of the product, allergy to the components of the
vaccine.
3. The history of allergic reactions to any vaccination in the past.
4. Serious post-vaccination reactions/complications associated with any vaccination in
the past.
5. Pregnancy and breastfeeding.
6. Military personnel on conscription.
7. Persons detained in pre-trial detention facilities and those serving sentences in
prison.
8. Children under the age of 18.
9. Symptoms of any disease at the time of inclusion in the study or if it has passed less
than 4 weeks since recovery.
10. The history of any acute respiratory disease within less than 3 months prior to
inclusion in the study.
11. The history of acute infectious or non-communicable diseases, exacerbation of chronic
diseases within less than 4 weeks before the start of the study.
12. The history of tuberculosis (pulmonary and extrapulmonary), cancer, autoimmune
diseases, skin diseases (pemphigus, psoriasis, eczema, atopic dermatitis).
13. Long-term use (more than 14 days) of immunosuppressive drug, systemic
glucocorticosteroids or immunomodulatory drugs within 6 months prior to the study.
14. Vaccination with any vaccine within one month prior to vaccination.
15. Taking immunoglobulin drugs or blood products within last 3 months prior to the study.
16. The history of treatment with human immunoglobulin drugs within, less than 6 months
since such treatment.
17. Donation (450 ml of blood or plasma and more) within less than 2 months prior to the
study.
18. Acute or chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine
system, as well as diseases of the gastrointestinal tract, liver, kidneys, surgery on
the gastrointestinal tract (except appendectomy).
19. The history of participation in other clinical trials within less than 3 months prior
to the start of this study.
20. Individuals with alcohol, drug dependence or drug addiction. Taking more than 10 units
of alcohol per week (1 unit of alcohol is equivalent to 1/2 litre of beer, 200 ml of
wine or 50 ml of alcohol) or anamnestic information about alcoholism, drug addiction,
and substance misuse. Individuals with positive results of urine examination for drugs
and/or with alcohol findings in the exhaled air during the visits.
21. Mental illness and neurasthenia.
22. Non-compliance with the inclusion criteria.
23. Women in the premenopausal period (the last menstruation ≤ 1 year prior to the signing
of informed consent) who are not surgically sterile and women who have reproductive
potential, but do not use acceptable birth controls or do not plan to use them
throughout the study and do not agree to a urine test for pregnancy during the
participation in the study.
24. Positive test for HIV, viral hepatitis B and C, lues venerea.
25. Other comorbidities that the researcher believes may interfere with the evaluation of
the study's objectives.
And:
1. The researcher's decision to exclude the volunteer for the benefit of the volunteer.
2. False inclusion (violation of inclusion and non-inclusion criteria) or the appearance
of non-inclusion criteria during the study.
3. The decision of the researcher or the Customer to exclude the volunteer from the study
due to a clinically significant deviation from the protocol/violation of the protocol.
4. Any undesirable phenomenon requiring the appointment of drugs not authorized by the
protocol of this study.
5. Refusal of a volunteer to continue to participate in the study or his/her
indiscipline.
6. Volunteer's desire to complete the study early for any reason.
7. Volunteer's failure to show up for a scheduled visit without the researcher's warning
or loss of communication with the volunteer.
Federal State Budgetary Institution of Healthcare "Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency" (FGBUZ MSCH-163, FMBA of Russia)
Koltsovo, Novosibirsk Region, Russian Federation
Vladimir I. Kuzubov, Principal Investigator
FGBUZ MSCH-163, FMBA of Russia